The present disclosure provides a dry-coated tablet comprising: an inner core containing, as active ingredients, (a) tegafur ((RS)-5-Fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione), (b) gimeracil, and (c) oteracil potassium and an outer shell. The outer shell preferably contains lactose, crystalline cellulose, hydroxypropyl cellulose, and crospovidone or partially pregelatinized starch.